Introduction
Clostridium difficile colitis has become an important clinical entity and currently affects 13 in 1,000 inpatients and accounts for 7,178 inpatients on any given day in American healthcare institutions [11] . There are *15,000 deaths each year in the United States which is about the same number of deaths attributable to abdominal aortic aneurysms [1] . The incidence of this entity has increased from 31 cases per 100,000 population in 1996-1984 cases per 100,000 population in 2005 [3] . Clostridium difficile has also dramatically grown in scope in terms of populations affected. For instance, there has been a 12-fold increased risk among children [12] . This article will discuss the reasons for the increase of the disease, current and emerging diagnostic and treatment strategies, as well as methods to prevent C. difficile infection.
Definition
Clostridium difficile infection (CDI) is defined by the presence of symptoms (usually diarrhea) plus a stool test positive for C. difficile toxins or colonoscopic and histopathologic findings revealing pseudomembranous colitis.
The New Strain
Over the past ten years, a more virulent strain of C. difficile has emerged. The new strain has been referred to by a number of different designations, such as BI, NAP1, toxinotype III, and ribotype 027, based upon the technology used to isolate or identify the species. This new strain produces 16-23 times more toxins A and B in vitro than do other strains. This new species is also fluoroquinolone resistant. These two features seem to contribute to the increase in morbidity and mortality that we have seen clinically [20] .
Proton Pump Inhibitors and Clostridium difficile
Proton pump inhibitors (PPI) work by increasing the stomach pH. This change in the gastrointestinal acidity alters the bodies innate defense mechanism against pathogenic organisms. Data suggests that there is a four-fold increase risk of C. difficile in hospitalized patients who are administered a PPI [9 •• ] . Additionally, PPI's have been shown to increase recurrence of C. difficile by 42 % [9 •• ]. It is prudent for physicians to balance these risks with the potential benefit when deciding whether to prescribe PPI therapy to a hospitalized patient [14] . 
Hand Hygiene
A recent study demonstrated that *95 % of all cases of CDI are due to healthcare exposure [1] . The Centers for Disease Control published a set of guidelines in 2002 that recommends clinicians use alcohol-based hand rubs for hand hygiene in most circumstances [2] . The spores of C. difficile are resistant to these alcohol-based hand rubs and the spores can easily be transferred by touch, including hand shaking after use of the alcohol-based hand rubs. Healthcare providers should wash their hands thoroughly with soap and water when caring for patients with CDI to decrease the chance of transmission [10] .
Diagnostic Testing
In general, only patients with diarrhea should be tested for C. difficile. The exception would be if an ileus is present. Testing asymptomatic patients should be avoided, including patients with recent infection (e.g., no ''test of cure''). Fecal leukocytes continued to be useful in patients with suspected CDI. They are present in about one-half of all patients with CDI. Stool culture is the gold standard, but is not practical clinically due to the time it takes to grow the culture. Enzyme immunoassay is a rapid test, but it is suboptimal to the cell cytotoxin assay. Toxin testing is the most important test clinically, but it is less sensitive than other tests. Some sites are now using a 2-step method where glutamate dehydrogenase enzyme immunoassay is performed if the toxin testing is positive. Polymerase chain reaction testing is a rapid, sensitive, and specific test, but more clinical evidence is needed before it is routinely recommended. Repeat testing during the same period of diarrhea is of limited value and should be discouraged [ 
Unexplained Leukocytosis
Leukocytosis is common in patients with CDI. One study demonstrated that 58 % of all patients with unexplained leukocytosis had C. difficile present [19] . Clinicians should be mindful of this association and consider CDI when caring for a hospitalized patient with unexplained leukocytosis.
Toxic Megacolon
Toxic megacolon is a potentially lethal complication of CDI. The incidence is \5 %. Early surgical interventions has been shown to decrease the mortality from 22 to 1.2 % [6, 7, 18] . It is important for clinicians to recognize patients with toxic megacolon in order to refer appropriately. Toxic megacolon is defined as radiographic evidence of colonic distention PLUS at least three of the following:
(1) Fever [ 38°C (2) Heart Rate [120 beats/min (3) Neutrophilic Leukocytosis [ 10,500/lL (4) Anemia
In addition, one of the following must be present as well:
(1) Dehydration (2) Altered sensorium (3) Electrolyte disturbances (4) Hypotension [17] Consider subtotal colectomy with preservation of rectum as the surgical procedure of choice in a patient with a toxic megacolon. Colonoscopies should be avoided in patients with a suspected toxic megacolon due to potential for perforation of the affected bowel. Antiperistaltic agents should be avoided in patients with or suspected CDI due to risk of precipitating toxic megacolon or obscuring symptoms. Bile acid resins, such as cholestyramine would be preferential agents for symptomatic relief and are not associated with toxic megacolon [ 
Treatment
It is important to discontinue the inciting antimicrobial as soon as possible when a patient is diagnosed with CDI. When severe or complicated CDI is suspected, initiate empirical treatment as soon as possible. Metronidazole (500 mg tid 9 10-14 days) is the drug of choice for the initial episode of mild-moderate CDI. Oral vancomycin (125 mg QID 9 10-14 days) is the drug of choice for an initial episode of severe CDI [11] . Oral vancomycin has a comparable rate of cure for patients with CDI, but a lesser chance for recurrence [22] (Table 1) .
It is important to recognize that metronidazole has potential adverse risks. Patients given metronidazole may have a disulfiram-like reaction if they consume alcohol while on therapy. There are potential carcinogenic properties to metronidazole as well. Thrombophlebitis has been associated with intravenous administration of metronidazole. Additionally, neurotoxicity (paresthesias, dysarthria, etc.) has been associated with long-term use of metronidazole. Therefore, long-term therapy with metronidazole should be avoided [4 •• ]. Additionally, there was a recent study which demonstrated the risk of death was significantly higher with intravenous metronidazole than with oral metronidazole or oral vancomycin. Thus, oral metronidazole should be given preferentially over the intravenous route whenever possible [21] .
Oral vancomycin is currently the mainstay of treatment for severe, complicated CDI. The recommended dose is 125 mg orally four times daily with or without intravenous metronidazole. If the patient has an ileus, vancomycin can be administered per rectum. The current cost for a 15-day supply of oral vancomycin is $1,990.97 [5] . Some hospital pharmacists are starting to administer the intravenous formulation of vancomycin orally to reduce hospital costs, but there are currently no studies to support this practice.
Fidaxomicin (Dificid) is a macrocyclic antibiotic with bactericidal properties that received FDA-approval on May 27, 2011. This medication is given twice daily for ten days and the most common side effects are nausea, vomiting, headache, abdominal pain, and diarrhea. A landmark study compared fidaxomicin to vancomycin and found no significant difference in cure rates between the two agents for CDI. However, there was a significant reduction in recurrences between fidaxomicin and vancomycin (15.4 vs.
%)
. However, the current cost of fidaxomicin is $2,800 for a 10-day course and this might restrict widespread use of this agent for now [15] .
Recurrence
Approximately 25 % of cases of CDI recur. Most recurrences present within 1-3 weeks of discontinuing treatment, but can present as much as 2-3 months later. If a patient has one recurrence, there is a 45-65 % chance of an additional recurrence. For the first recurrence of mildmoderate CDI, metronidazole is the preferred antimicrobial. For each subsequent recurrence, oral vancomycin with a tapering dose is the recommended therapy. In these cases, the patient should receive vancomycin 125 mg orally four times daily for 10-14 days, then 125 mg twice daily for a week, then 125 mg daily for a week, then 125 mg every two or three days for 2-8 weeks
Infection Control
Healthcare workers and visitors must use gloves and gowns when examining or visiting a patient with CDI. Hand hygiene with an antimicrobial soap should be used and alcohol-based hand rubs should be avoided. Patients with known or suspected CDI should be admitted or transferred to a private room. Identification of asymptomatic carriers of C. difficile is not recommended. Additionally, reusable electric thermometers should be avoided and disposable thermometers should be used for rectal temperature recordings. Rooms occupied by patients with CDI should be cleaned with chlorine-containing agents or other sporicidal agents [4 •• ] .
Probiotics
Probiotics are live, nonpathogenic bacteria capable of colonizing the colonic mucosa. There is currently no evidence of benefit in severe CDI. They may have some role for recurrent mild-moderate disease (S. boulardii), but the evidence is inconclusive. Furthermore, probiotics are not recommended to prevent primary CDI, as there is limited data to support this approach and there is a potential risk of 
Fecal Bacteriotherapy
There has been a significant amount of interest recently in the use of fecal bacteriotherapy in patients with recurrent C. difficile. The rationale of this approach is that stool from a healthy donor might restore normal enteric flora in a patient affected with recurrent CDI and prevent recurrence. This is performed by taking stool from a healthy donor and inserting via enema, colonoscope, nasoduodenal or jejunal tube (an insertion route not recommended by these authors due to potential for patient dysgeusia). A success rate up to 87 % of stopping recurrences have been reported in small observational studies. [13, 16] 
Conclusions
Clostridium difficile colitis is an ever present danger and constant risk for all hospitalized patients. Its continued prevalence throughout our hospital communities serves as a constant reminder that we as health care providers must stay abreast of the most current ways to protect, diagnose, and treat our patients. With the rising cost of healthcare it is imperative that we stress a focus on preventing transmission via barrier methods like gowning and gloving as well as consistent and appropriate use of hand washing and sporicidal agents when in contact with a C. difficile infected patient. Most importantly, a solid understanding of treatment options which not only includes proper antibiotic utilization but also proper duration of treatment, are cornerstone elements to preventing the severe complications and recurrence in the at risk patient populations that frequent our hospital wards.
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